Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: 1400 milligram Xentuzumab; Drug: 1000 milligram Xentuzumab; Drug: 750 milligram Xentuzumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02145741

1280.15

Details and patient eligibility

About

This open-label dose escalation phase I trial, 1280.15, is with the first administration of BI 836845 in Japanese patients with various types of advanced solid tumours. The rationale behind this study is to identify the maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours as weekly intravenous administration.

Enrollment: 21 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients who meet all of the following inclusion criteria by the judgment of investigator are eligible to receive the study treatment:

1. Patients with cytologically or histologically confirmed solid tumours that are refractory to standard therapy, for whom no standard therapy of proven efficacy exists, or who are not amenable to establish treatment options
2. Age >=20 years old
3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
4. Written informed consent that is consistent with Good Clinical Practice (GCP) guidelines

Exclusion criteria

Patients who apply any of the following exclusion criteria by the judgment of investigator are not eligible to receive the study treatment:

1. Active infectious disease to be incompatible with the study treatment

2. Patients who do not have sufficient major organ function and meet any of the following test results at screening period

   • Cardiac left ventricular function with resting ejection fraction <=50% as determined by echocardiography (ECHO) or multiple-gated acquisition scan (MUGA)
   • Absolute neutrophil count <1500/µL
   • Platelets <100 000/µL
   • Total bilirubin >1.5 × the upper limit of normal (ULN)
   • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 × ULN (in case of known liver metastases, AST and/or ALT >5 × ULN)
   • Creatinine >1.5 × ULN
   • Haemoglobin <9 g/dL
   • HbA1c >=8% and fasting glucose >8.9 mmol/L (>160 mg/dL)

3. Serious illness or concomitant non-oncological disease including severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may compromise the safety of the patient during the study, affect the patient's ability to complete the study, or interfere with interpretation of study results considered by the investigator to be incompatible with the study treatment

4. History of thrombosis (except tumour invading great vessels) within 1 year before start of study treatment or if concurrent anticoagulation required

5. Patients not recovered from any therapy-related toxicities from previous chemotherapies, hormonal therapies, immunotherapies, molecular-targeted therapies, or radiotherapies to Common Terminology Criteria for Adverse Events (CTCAE) grade <=1

6. Patients who have not recovered from any previous surgery and major surgery within the last 4 weeks before start of study treatment

7. Patients with untreated or symptomatic brain metastases.

8. Patients who have been treated with any of the following within 4 weeks before start of study treatment: chemotherapies, immunotherapies, radiotherapies (within 2 weeks before start of study treatment for local palliative radiotherapies for the treatment of brain metastasis or extremities), biological therapies, molecular-targeted therapies, hormonal therapies for breast cancer within 2 weeks before start of study treatment, or treatment with other investigational drugs.

9. Patients who have used any investigational drug within 4 weeks before start of study treatment or who have planned concomitantly use with the trial.

10. Patients unable to comply with the clinical trial protocol (CTP)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Parallel Assignment

Masking: None (Open label)

---

21 participants in 3 patient groups

750 milligram Xentuzumab

Experimental group

Description:

750 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

Treatment:

Drug: 750 milligram Xentuzumab

1000 milligram Xentuzumab

Experimental group

Description:

1000 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

Treatment:

Drug: 1000 milligram Xentuzumab

1400 milligram Xentuzumab

Experimental group

Description:

1400 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

Treatment:

Drug: 1400 milligram Xentuzumab